PATENT CLAIM ANALYSIS

Application Number: 15899682
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-07
Patent Classification: ["514", "04400A"]

Abstract:
The present invention discloses c-MYC-siRNA formulation as a potential therapeutic target for cisplatin-resistant ovarian cancer. It is disclosed targeting c-MYC with small interfering RNA (siRNA) in the cisplatin-resistant ovarian cancer cell line inducing a significant cell growth arrest and inhibition of cell proliferation. Apoptosis and arrest of cell cycle progression were also observed after c-MYC-siRNA-based silencing of c-MYC. Furthermore, delivering nanoliposomal c-MYC-siRNA, decreased tumor weight and number of tumor nodules compared with a liposomal-negative control siRNA.

Claim (Index 40):
The compound of  claim 31 , wherein the cancer cells are brain cells.

Metadata:
- Claim Count in Document: 59.0
- Percentile: 88.0
- Lexical Diversity: 1.37705
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14681875', '11911639', '12527684', '15320903', '13129349']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7736628490747853
- 35 USC 102 Novelty (BERT): 0.5457802563945002
- Combined Prediction Score: 0.7508745898067568
- Mean Citation Score: 344.327304
- Max Citation Score: 514.0765
- Similarity Product: 192.87225085358327

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test